Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yunpeng Yang(Sun Yat-sen University), Li Zhang(Gdańsk Medical University), Weineng Feng(First People's Hospital of Foshan), Giovanni Selvaggi, Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yi Hu(Union Hospital), Zhendong Zheng(General Hospital of Shenyang Military Region), Yuanqing Fu(Westlake University), Yanqiu Zhao(Henan Cancer Hospital), Jianying Zhou(First Affiliated Hospital Zhejiang University), Gang Wu(Hubei University of Chinese Medicine), Xiaobin Yuan(Betta Pharmaceuticals (China)), Youling Gong(Dalian Medical University), Kewei Ma(Jilin University), Wei Song(Xuzhou Medical College), Shijun Zhao(Second Hospital of Shandong University), Yubiao Guo(Sun Yat-sen University), Jian Fang(Peking University), Jianhua Chen(Xinjiang Medical University), Yuan Chen(China General Nuclear Power Corporation (China)), Tao Wang(Pfizer (United States)), Feng Ye(First Affiliated Hospital of Xiamen University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Zhuang Yu(Shanghai East Hospital), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Gaofeng Li(Sir Run Run Shaw Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Li Mao(Washington State University), Ning Wu(Regeneron (United States)), Lieming Ding(Betta Pharmaceuticals (China)), Wu Zhuang(Hunan University), Shanshan Xiao(University of Science and Technology of China), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Jianya Zhou(First Affiliated Hospital Zhejiang University), Xiaoqing Liu(Chinese PLA General Hospital), Yiping Zhang(National Health and Family Planning Commission)
The Lancet Respiratory Medicine
October 15, 2019
10.1016/s2213-2600(19)30252-8
Cited by 139

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
|Cell|2016|1.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k